In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Kathryn LandeSalk Institute for Biological Studies, La Jolla, CA, USA.
Allison Y LouieSalk Institute for Biological Studies, La Jolla, CA, USA.
Deann GuanSalk Institute for Biological Studies, La Jolla, CA, USA.
Åsa B GustafssonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-6347-8210 Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8MProject 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6MPathways in Biological Sciences Training ProgramT32GM133351 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew Daugherty, Randolph Y. Hampton · 2020 to 2026
$9.9MSalk Institute Cancer Training GrantT32CA009370 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Diana Clare Hargreaves, Jan Karlseder · 1986 to 2026
$8.6MSan Diego Nathan Shock CenterP30AG068635 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SHADEL, GERALD · 2020 to 2024
$6.0MUC San Diego Medical Scientist Training ProgramT32GM154642 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Neil C Chi, Mary Kathleen Lewinski · 2025 to 2026
$2.9MTracking the Mechanisms of Adaptation to Autophagy InhibitionDP2CA290705 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Christina G Towers · 2023 to 2026
$2.9MAutophagy and Megamitochondria in Cardiac Aging and Heart FailureR01HL157265 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUSTAFSSON, ASA B. · 2021 to 2024
$1.9MUnderstanding omega-3 and 6 fatty acid dependent regulation of inflammatory signals in pancreatic cancerU01CA293476 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Susan M Kaech · 2025 to 2026
$1.5MQuantitative Neuroscience Spanning Molecules, Cells, Circuits, and BehaviorT32NS136094 · NINDS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EDWARD M CALLAWAY, SAMUEL L. PFAFF · 2024 to 2026
$1.4MMitochondrial Regulation of Interferon Response in MelanomaF31CA278581 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI JOHNSON, MELISSA · 2023 to 2025
$106kNCI NIH HHS DP2 CA290705NCI NIH HHS F31 CA278581NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA030199NCI NIH HHS T32 CA009370NCI NIH HHS U01 CA293476NHLBI NIH HHS F30 HL178290NHLBI NIH HHS R01 HL157265NIA NIH HHS P01 AG073084NIA NIH HHS P30 AG068635NIGMS NIH HHS T32 GM133351NIGMS NIH HHS T32 GM154642NINDS NIH HHS T32 NS136094
6 · The paper itselfAbstract
Mitohormesis, whereby transient mitochondrial stress induces adaptive signaling, promotes organismal resilience and longevity in invertebrates, but how this operates in mammals and the underlying metabolic signals involved remain unclear. Using a mouse model of mitohormesis, we show that transient mitochondrial superoxide stress during embryogenesis reprograms the adult heart to enhance mitochondrial biogenesis and antioxidant capacity. These adaptations confer protection against mitochondrial and oxidative injury in models of doxorubicin-induced cardiotoxicity, preserving mitochondrial content and preventing cardiac dysfunction and remodeling. Using a cell model of superoxide-mediated mitohormesis, we find that inhibition of mitochondrial aconitase promotes citrate export to the cytosol, where its conversion to acetyl-coenzyme A drives histone acetylation and mitohormetic protection from oxidative stress. Preventing mitochondrial citrate export abolishes these adaptations, while
Indexed as
Cardiotonic AgentsCitric AcidMitochondriaMitochondria, HeartSuperoxidesAcetylationAconitate HydrataseAnimalsDoxorubicinHistonesMiceOxidative StressAconitate HydrataseCardiotonic AgentsCitric AcidDoxorubicinHistonesSuperoxides
Identifiers
PMID42696571
PMCPMC13544202
What Socratic holds
Textmetadata
Read underepoch 390